Table 1 Baseline characteristics of the patients
|  | N = 58 |
|---|---|
Age (years) | 60 (33–86) |
Sex, male | 53 (91.4) |
Etiology of HCC | |
 HBV |  |
 Others |  |
Child-Pugh score | |
 A5 | 38 (65.5) |
 A6 | 20 (34.5) |
ALBI grade | |
 1 | 26 (44.8) |
 2 | 32 (55.2) |
AFP | 594 (10–9242) |
PIVKA-II | 4899 (796–25,522) |
BCLC stage | |
 B | 15 (25.9) |
 C | 43 (74.1) |
Vascular invasion (yes) | 18 (31.0) |
Extrahepatic meta (yes) | 36 (62.1) |
 Lung | 20 (34.5) |
 Lymph node | 10 (17.2) |
 Bone | 8 (13.8) |
 Adrenal gland | 2 (3.4) |
 Others | 9 (15.5) |
Sorafenib treatment duration (months) | 2.9 (1.5–28.1) |